Announcements Trials
Browse Landscape

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Conditions

Neoplasms 4Heart Diseases 3Carcinoma, Non-Small-Cell Lung 3Vascular Diseases 2Cardiotoxicity 2Small Cell Lung Carcinoma 1Metabolic Diseases 1Liver Neoplasms 1Heart Failure 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Cardiovascular Diseases 1Cancer Therapy-related Cardiovascular Toxicity 1

Interventions

Echocardiography 11Electrocardiography 5Trastuzumab 4Social Determinants of Health 2Doxorubicin 2Chemoradiotherapy 2Blood Specimen Collection 2Antineoplastic Agents 2Vascular Stiffness 1Standard of Care 1Resistance Training 1Pulse Wave Analysis 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Immunomodulating Agents 1Hematologic Tests 1Gonadal Steroid Hormones 1Exercise Test 1EGFR tyrosine kinase inhibitor 324674 1Clinical Laboratory Techniques 1Cisplatin 1Cardiography, Impedance 1Anthracyclines 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Cardiotoxicity × Antineoplastic Agents × Clear all
NCT03882580 2023-04-24

NEOCARDIO

Groupe Hospitalier Pitie-Salpetriere

Unknown
5,000 enrolled

Heart Diseases, Heart Failure, Metabolic Diseases, Vascular Diseases, Drug-Related Side Effects and Adverse Reactions, Cardiotoxicity

NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

Completed
500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡